NowVertical Group to Host Live Corporate Webinar on July 12th at 10:00 am ET
TORONTO, June 24, 2024 (GLOBE NEWSWIRE) -- NowVertical Group Inc. (TSXV: NOW) (OTCQB: NOWVF) (“NOW” or the “Company”) announces that...
Month: June 2024
Red Pine Announces Completion of Verification of Gold Assay Results Database to Support Updated Mineral Resource Estimate
TORONTO, June 24, 2024 (GLOBE NEWSWIRE) -- Red Pine Exploration Inc. (TSXV: RPX, OTCQB: RDEXF) (“Red Pine” or the “Company”)...
Entrada Therapeutics Announces $100 Million Registered Direct Offering
BOSTON, June 24, 2024 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) is a clinical-stage biopharmaceutical company aiming to transform...
24/7 Market News Snapshot 24 Jun 2024 – Regulus Therapeutics Inc. (NASDAQ: RGLS)
DENVER, Colo., 24 June, 2024 (247marketnews.com) - (Nasdaq: RGLS) are discussed in this article.Regulus Therapeutics Inc. (RGLS) is currently experiencing...
Ceva Extends its Smart Edge IP Leadership, Adding New TinyML Optimized NPUs for AIoT Devices to Enable Edge AI Everywhere
- Ceva-NeuPro-Nano NPUs deliver optimal balance of ultra-low power and best performance in small area to efficiently execute TinyML workloads...
Altair Announces Material Collaboration with HP Inc.
HP data will bolster Altair® Material Data Center™ bridging gap between design and production of 3D-printed parts TROY, Mich., June...
Alnylam Reports Positive Topline Results from HELIOS-B Phase 3 Study of Vutrisiran, Achieving Statistical Significance on Primary and All Secondary Endpoints in Both Overall and Monotherapy Populations
− Achieved 28% and 33% Reduction in Composite of All-Cause Mortality and Recurrent Cardiovascular Events in the Overall and Monotherapy...
Adicet Bio Announces FDA Clearance of IND Application for ADI-270 in Renal Cell Carcinoma
ADI-270 is the first gamma delta 1 CAR T candidate to enter clinical development for solid tumors Phase 1 clinical...
Village Farms International to Present at iAccess Alpha Virtual Conference June 25 and 26
VANCOUVER, British Columbia and ORLANDO, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Village Farms International, Inc. (“Village Farms” or “the...
Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor
DUBLIN, June 24, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human...
Marlborough’s Investment Fund Services Ltd Enters Strategic Partnership with SS&C
Agreement creates a 'centre of excellence' for fund administration in the U.K. WINDSOR, Conn., June 24, 2024 /PRNewswire/ -- SS&C Technologies...
Scholar Rock Announces New SRK-439 Preclinical Data Showing Significant Lean Mass Preservation and Attenuation of Fat Mass Rebound Following GLP-1 Receptor Agonist Withdrawal
- SRK-439, a myostatin inhibitor, is part of Scholar Rock’s industry-leading anti-myostatin portfolio - Obesity program continues to progress, with...
REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
ROCKVILLE, Md., June 24, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it initiated enrollment in a new cohort of...
Regulus Therapeutics Announces Positive Topline Data from the Third Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Continued mechanistic dose response observed following completion of 3 mg/kg dose level based on urinary biomarker analyses Percent change from...
Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment
~ New RT-114 obesity program combines ProGen’s FC Fusion protein conjugated GLP-1/GLP-2 dual agonist, PG-102, with the RaniPill® capsule designed...
Progyny, Inc. Announces Enhanced Global Services with Acquisition of Apryl
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women’s health...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence
Wayne Pisano, Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast cancer...
Omega Therapeutics Announces Election of Richard N. Kender to Board of Directors
CAMBRIDGE, Mass., June 24, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the...
Michael Finegan Named Chair of the Orthofix Board of Directors
Contacts Media Relations Denise Landry DeniseLandry@Orthofix.com 214.937.2529 Investor Relations Julie Dewey JulieDewey@Orthofix.com 209.613.6945 Orthofix Medical Inc. (NASDAQ:OFIX), a leading global...
Manhattan Bridge Capital, Inc. Announces Payment of Quarterly Dividend
GREAT NECK, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (NASDAQ: LOAN) announced today that, in accordance...
Liberty Broadband Corporation Announces Proposed Private Offering of Exchangeable Senior Debentures
Contacts Liberty Broadband Corporation Shane Kleinstein, 720-875-5432 Liberty Broadband Corporation (“Liberty Broadband”) (Nasdaq: LBRDA, LBRDK, LBRDP) announced today that it...
Liberty Broadband Corporation Announces Proposed Private Offering of Exchangeable Senior Debentures
Contacts Liberty Broadband Corporation Shane Kleinstein, 720-875-5432 Liberty Broadband Corporation (“Liberty Broadband”) (Nasdaq: LBRDA, LBRDK, LBRDP) announced today that it...
Liberty Broadband Corporation Announces Proposed Private Offering of Exchangeable Senior Debentures
Contacts Liberty Broadband Corporation Shane Kleinstein, 720-875-5432 Liberty Broadband Corporation (“Liberty Broadband”) (Nasdaq: LBRDA, LBRDK, LBRDP) announced today that it...
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY
PLYMOUTH MEETING, Pa., June 24, 2024 /PRNewswire/ -- Harmony Biosciences (Nasdaq: HRMY) today announced that the U.S. Food and Drug...
Canoo Received Discounted Manufacturing Assets at Oklahoma Facilities
JUSTIN, Texas, June 24, 2024 (GLOBE NEWSWIRE) -- Canoo Inc. (Nasdaq: GOEV), a high-tech advanced mobility company, today announced that...
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced...
CytoSorbents Announces Regulatory Approval of CytoSorb® in Taiwan
PRINCETON, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions...
Recent AGA Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences’ TissueCypher® Test
Castle’s TissueCypher test has been shown to improve the risk stratification of patients with Barrett’s esophagus (BE)1,2 Contacts Investor Contact:...
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
ALACHUA, Fla. and TAMPA, Fla., June 24, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing...
ANI Pharmaceuticals to Further Expand Rare Disease Business through Acquisition of Alimera Sciences
Conference call scheduled for today at 8:30 a.m. ETPRINCETON, N.J. and ATLANTA, June 24, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals,...
Premier American Uranium and American Future Fuel Announce Updated Mineral Resource Estimate for the Cebolleta Project, Setting the Stage for Planned Expansion Drilling
TORONTO, June 24, 2024 (GLOBE NEWSWIRE) -- Premier American Uranium Inc. (“PUR” or “Premier American Uranium”) (TSXV: PUR) (OTCQB: PAUIF)...
Cielo Announces Private Placement of Convertible Debenture Units for up to $2.87 Million
CALGARY, Alberta, June 24, 2024 (GLOBE NEWSWIRE) -- Cielo Waste Solutions Corp. (TSXV:CMC; OTCQB:CWSFF) (“Cielo” or the “Company”), a company...
eFFECTOR Therapeutics Announces it will Wind Down Operations as it Seeks Strategic Alternatives and Expects to be Delisted from Nasdaq
SOLANA BEACH, Calif. and REDWOOD CITY, Calif., June 24, 2024 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR) today announced...
Green Shift Commodities Closes Final Tranche of Private Placement and Enters Definitive Agreement for Sale of Argentina Lithium Assets
TORONTO, June 24, 2024 (GLOBE NEWSWIRE) -- Green Shift Commodities Ltd. (TSXV: GCOM), (“Green Shift” or the “Company”) is pleased...
Nuclear Fuels Appoints Gregory Huffman as Chief Executive Officer
CSE:NFOTCQX:NFUNF VANCOUVER, BC, June 24, 2024 /PRNewswire/ - Nuclear Fuels Inc. (CSE: NF) (OTCQX: NFUNF) ("Nuclear Fuels" or the "Company") today...
OceanaGold Receives $30M for Sale of the Blackwater Project
VANCOUVER, BC, June 24, 2024 /PRNewswire/ - OceanaGold Corporation (TSX: OGC) (OTCQX: OCANF) ("OceanaGold" or the "Company") confirms it has...
BioNTech und DualityBio erhalten Fast-Track-Status der FDA für Antikörper-Wirkstoff-Konjugat-Kandidat BNT324/DB-1311 bei Prostatakrebs
MAINZ, Deutschland, und SHANGHAI, China, 24. Juni 2024 – BioNTech SE (Nasdaq: BNTX, „BioNTech“) und Duality Biologics (Suzhou) Co., Ltd. („DualityBio“) gaben heute bekannt,...
Canada Nickel Provides Corporate Update and Announces US$15 Million Loan Facility with Auramet International, Inc.
TORONTO, June 24, 2024 /PRNewswire/ - Canada Nickel Company Inc. ("Canada Nickel" or the "Company") (TSXV: CNC) (OTCQX: CNIKF) today announces...
Hut 8 Announces $150 Million Strategic Investment from Coatue to Partner in Building Next Generation AI Infrastructure Platform
Funding will accelerate growth in Hut 8’s data center portfolioReinforces Hut 8’s position as a market leader in sourcing, developing,...
G1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)
- PRESERVE 2 Did Not Achieve Statistical Significance in the Primary Endpoint of Overall Survival (OS) in the Intent-to-Treat (ITT)...